EGRX Eagle Pharmaceuticals, Inc.

73.89
-2.49  -3%
Previous Close 76.38
Open 76.10
Price To book 6.98
Market Cap 1.13B
Shares 15,298,000
Volume 453,160
Short Ratio 14.66
Av. Daily Volume 322,436

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA date October 30, 2017.
Ready-to-dilute (RTD) Pemetrexed Injection
Nonsquamous Non-Small Cell Lung Cancer (NSCLC) and Mesothelioma
PDUFA date under priority review July 23, 2017.
Ryanodex
Exertional heat stroke (EHS)
Tentative approval July 2 2014. Teva has also received orphan drug and related pediatric exclusivity expiring in September 2015 and May 2016 for the CLL and NHL indications, respectively.
EP-3101 (bendamustine RTD)
Chronic lymphocytic leukemia; Indolent non-Hodgkin's lymphoma - cancer
CRL March 18 2016. FDA requested further characterization of bivalirudin-related substances in the drug product
KANGIO (bivalirudin injection)
Percutaneous Coronary Intervention (PCI) and Percutaneous Transluminal Coronary Angioplasty (PTCA)
Approved December 24, 2015.
Docetaxel Injection
Breast, non-small cell lung, prostate gastric adenocarcinoma, and head and neck cancer
Approved July 22, 2014 under priority review.
Ryanodex
Malignant hyperthermia - cancer

Latest News

  1. Teva Pharma, Eagle Pharma, Depomed Among Slew Getting Price Haircuts
  2. Eagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : EGRX-US : May 16, 2017
  3. Eagle Pharmaceuticals Appoints Pete A. Meyers as Chief Financial Officer
  4. Edited Transcript of EGRX earnings conference call or presentation 8-May-17 12:30pm GMT
  5. Eagle Pharmaceuticals, Inc. to Present at Bank of America Merrill Lynch 2017 Health Care Conference
  6. Eagle Pharmaceuticals posts 1Q profit
  7. Eagle Pharmaceuticals, Inc. Reports First Quarter 2017 Results
  8. Eagle Pharmaceuticals, Inc. to Discuss First Quarter 2017 Financial Results on May 8, 2017
  9. Eagle Pharmaceuticals, Inc. to Present at 42nd Annual Deutsche Bank Health Care Conference
  10. ETFs with exposure to Eagle Pharmaceuticals, Inc. : April 24, 2017
  11. 15 companies with outsized sales growth and widening profit margins
  12. FDA Grants Priority Review for Eagle Pharmaceuticals’ Ryanodex NDA for the Treatment of Exertional Heat Stroke
  13. 3 Top Biotech Stocks to Buy in 2017
  14. Eagle Pharma Cancer Drug Secures New Patents
  15. Eagle Pharmaceuticals Announces Three New Patents Issued for Bendeka
  16. Eagle Pharmaceuticals Appoints Richard A. Edlin to Board of Directors
  17. New Strong Sell Stocks for March 6th
  18. Eagle Pharmaceuticals, Inc. :EGRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 3, 2017
  19. Edited Transcript of EGRX earnings conference call or presentation 1-Mar-17 1:30pm GMT